Type of non Hodgkin's lymphoma-Other-Small cell lymphocytic lymphoma Posts on Medivizor
Navigation Menu

Type of non Hodgkin’s lymphoma-Other-Small cell lymphocytic lymphoma Posts on Medivizor

Surviving cancer – is there a greater risk of cardiovascular disease long-term?

Posted by on Sep 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors.  They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...

Read More

Combination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma

Posted by on May 9, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients.  Some background Patients with NHL are often treated with targeted therapies....

Read More

Does G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?

Posted by on May 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...

Read More

What are the long-term outcomes following bendamustine treatment?

Posted by on Mar 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...

Read More

Searching for patients with relapsed or refractory non-Hodgkin’s lymphoma to test the effectiveness of a PI3K inhibitor alone or with other drugs

Posted by on Sep 11, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness and safety of ublituximab (TG-1101) and TGR-1202 with or without bendamustine (Treanda), as well as TGR-1202 alone in treating patients with relapsed or refractory non-Hodgkin’s lymphoma. The primary outcome will be measured by the overall response.   The details...

Read More